Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY. Cahn P, et al. Among authors: hung cc. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275. J Acquir Immune Defic Syndr. 2020. PMID: 31834000 Free PMC article. Clinical Trial.
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Tebas P, Sension M, Arribas J, Duiculescu D, Florence E, Hung CC, Wilkin T, Vanveggel S, Stevens M, Deckx H; ECHO and THRIVE Study Groups. Tebas P, et al. Among authors: hung cc. Clin Infect Dis. 2014 Aug 1;59(3):425-34. doi: 10.1093/cid/ciu234. Epub 2014 Apr 11. Clin Infect Dis. 2014. PMID: 24729492 Clinical Trial.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M. Llibre JM, et al. Among authors: hung cc. Lancet. 2018 Mar 3;391(10123):839-849. doi: 10.1016/S0140-6736(17)33095-7. Epub 2018 Jan 6. Lancet. 2018. PMID: 29310899 Clinical Trial.
Dolutegravir-rilpivirine coformulation.
Sun HY, Chang SY, Hung CC. Sun HY, et al. Among authors: hung cc. Curr Opin HIV AIDS. 2018 Jul;13(4):320-325. doi: 10.1097/COH.0000000000000466. Curr Opin HIV AIDS. 2018. PMID: 29553948 Review.
1,310 results